Christian Heiss։ New Evidence on Drug-Coated Technologies in Chronic Limb-Threatening Ischemia
Christian Heiss, Associate Head of Medical School (Research and Innovation) at the University of Surrey, Professor and NHS Consultant in Interventional Cardiovascular Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in medRxiv, adding:
”Excited to share our new medRxiv preprint on drug-coated devices in chronic limb-threatening ischemia (CLTI).
In a real-world cohort of patients undergoing infrainguinal endovascular therapy, drug-coated device use was not associated with increased adjusted 1-year mortality and was associated with improved wound healing — a patient-relevant outcome that may capture early clinical benefit better than revascularization or amputation endpoints alone.
Exploratory analyses also suggested favourable outcomes with sirolimus-coated balloons, supporting the need for dedicated comparative studies of limus-based technologies in CLTI.
As always, this is a preprint and has not yet undergone peer review.”
Title: Drug-Coated Devices, Wound Healing, and Mortality After Endovascular Therapy for Chronic Limb-Threatening Ischemia
Authors: Yonggu Lee, Alexander D. Rodway, Gary D. Maytham, Nikolaos Ntagiantas, Ivan Walton, Felipe Pazos-Casal, Charlotte Allan, Marianne Brodmann, Oliver Schlager, Jenny Harris, Christian Heiss
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?
-
Sep 20, 2026, 00:50A Shared Platelet Factor 4–Targeted Immune Mechanism in Adenovirus Infection – NEJM